Mesangiolysis in Chronic Active Antibody-mediated Rejection in Kidney Transplant Biopsies

被引:0
|
作者
Suto, Yuki [1 ]
Oguchi, Hideyo [1 ,6 ]
Tochigi, Naobumi [2 ]
Mikami, Tetuo [3 ]
Shinoda, Kazunobu [1 ,4 ]
Honda, Kazuho [5 ]
Kounoue, Noriyuki [1 ]
Hashimoto, Junya [1 ]
Muramatsu, Masaki [1 ]
Itabashi, Yoshihiro [1 ]
Sakai, Ken [1 ]
机构
[1] Toho Univ, Fac Med, Dept Nephrol, Tokyo, Japan
[2] Toho Univ, Fac Med, Dept Surg Pathol, Tokyo, Japan
[3] Toho Univ, Fac Med, Dept Pathol, Tokyo, Japan
[4] St Marianna Univ, Sch Med, Dept Urol, Kawasaki, Kanagawa, Japan
[5] Showa Univ, Sch Med, Dept Anat, Tokyo, Japan
[6] Toho Univ, Fac Med, Dept Nephrol, 6-11-1 Omori Nishi, Ota ku, Tokyo 1438541, Japan
关键词
CLASSIFICATION; INJURY;
D O I
10.1159/000531573
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: This study aimed to determine if immune or non-immune and acute or chronic lesions associated with mesangiolysis (MGLS) occurred in biopsy-proven pathological chronic active antibody-mediated rejection (P-CAABMR) in kidney transplant biopsies. Methods: We evaluated MGLS in 41 patients with biopsy findings of P-CAABMR from January 2016 to December 2019. Histological scoring was evaluated by Banff classification. Multivariate logistic regression analysis was performed using a forward selection method. Results: Fifteen of the 41 P-CAABMR biopsies (36.6%) cases showed MGLS. The estimated glomerular filtration rate (eGFR) was significantly lower in the MGLS-positive compared with the MGLS-negative group, and proteinuria was significantly higher in the MGLS-positive compared with the MGLS-negative group. In the clinical model, multivariate analysis was performed using covariates of eGFR and duration after transplantation significantly correlated with MGLS by simple analysis, in addition to type of calcineurin inhibitor use (tacrolimus or cyclosporine), donor-specific antibodies, diabetes, and hypertension grade defined by use of antihypertensive therapy or/and blood pressure level. Only hypertension grade was significantly correlated with MGLS. In the pathological model, multivariate analysis was performed using the presence of FSGS and the aah and cg scores significantly correlated with MGLS by simple analysis, in addition to g and ptc scores. The cg score was significantly correlated with hypertension grade, duration after transplantation, g, ah and aah. Conclusion: Lower graft function and higher proteinuria was observed in MGLS of P-CAABMR. The Banff cg score was independently related to MGLS in multivariate analysis. Sustained glomerulitis, calcineurin inhibitor nephrotoxicity, and hypertension may cause Banff cg lesions, leading to MGLS in P-CAABMR.
引用
收藏
页码:14 / 21
页数:19
相关论文
共 50 条
  • [31] Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation
    Kumar, D.
    Gupta, G.
    Reeve, J.
    Sanghi, P.
    Bobba, S.
    Levy, M.
    Bhati, C.
    Kimball, P.
    Fattah, H.
    King, A.
    Massey, H.
    Halloran, P.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 310 - 310
  • [32] REFRACTORY ANTIBODY-MEDIATED REJECTION IN KIDNEY-PANCREAS TRANSPLANT
    Xu, Jimmy
    Gorton, Lauren
    Neidich, Alon
    Craig, Julia
    Murphy, Katie
    Graff, Ralph
    Tuttle, Betsy
    Bastani, Bahar
    Horton, Peter
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (05) : A115 - A115
  • [33] Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
    Jordan, S. C.
    Vescio, R.
    Toyoda, M.
    Ammerman, N.
    Huang, E.
    Peng, A.
    Sethi, S.
    Najjar, R.
    Lim, K.
    Vo, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 1062 - 1062
  • [34] Current problems of chronic active antibody-mediated rejection
    Takeda, Asami
    Horike, Keiji
    Ohtsuka, Yasuhiro
    Inaguma, Daijo
    Goto, Norihiko
    Watarai, Yoshihiko
    Uchida, Kazuharu
    Morozumi, Kunio
    [J]. CLINICAL TRANSPLANTATION, 2011, 25 : 2 - 5
  • [35] Retrospective Analysis of Kidney Transplant Recipients with Antibody-Mediated Rejection
    Pineiro, G.
    Desousa, E.
    Villarreal, J.
    Lozano, M.
    Cid, J.
    Sole, M.
    Oppenheimer, F.
    Diekmann, F.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 536 - 536
  • [36] THE PROGNOSTIC FACTORS IN CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION
    Zniber, A.
    Pernin, V.
    Ramouneau-Pigot, A.
    Kanouni, T.
    Serre, J. E.
    Garrigue, V.
    Eliaou, J. F.
    Mourad, G.
    [J]. TRANSPLANT INTERNATIONAL, 2013, 26 : 8 - 8
  • [37] Antibody-mediated rejection diagnosed in early protocol biopsies in high immunological risk kidney transplant recipients
    Arana, Carolt
    Hermida, Evelyn
    Rovira, Jordi
    Caro, Jose Luis
    Cucchiari, David
    Larque, Ana Belen
    Palou, Eduard
    Torres, Juan
    Montagud-Marrahi, Enrique
    Cuadrado-Payan, Elena
    Rodriguez, Diana
    Cacho, Judit
    Gonzalez, Angela
    Reinoso, Johanna
    Nicolau, Carlos
    Esforzado, Nuria
    Torregrosa, Vicente
    Pineiro, Gaston
    Revuelta, Ignacio
    Cofan, Federico
    Diekmann, Fritz
    Ventura-Aguiar, Pedro
    Oppenheimer, Federico
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [38] Rationale for the IMAGINE study for chronic active antibody-mediated rejection (caAMR) in kidney transplantation
    Nickerson, Peter W. W.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 38 - 44
  • [39] Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation
    Muller, Yannick D.
    Ghaleb, Nseir
    Rotman, Samuel
    Vionnet, Julien
    Halfon, Matthieu
    Catana, Emmanuelle
    Golshayan, Dela
    Venetz, Jean-Pierre
    Aubert, Vincent
    Pascual, Manuel
    [J]. TRANSPLANT INTERNATIONAL, 2018, 31 (04) : 451 - 455
  • [40] RITUXIMAB AS MONOTHERAPY FOR THE TREATMENT OF CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION
    Muller, Yannick
    Ghaleb, Nseir
    Rotman, Samuel
    Catana, Emmanuelle
    Golshayan, Dela
    Venetz, Jean-Pierre
    Aubert, Vincent
    Pascual, Manuel
    [J]. TRANSPLANT INTERNATIONAL, 2017, 30 : 553 - 554